PAR. SP, page-896

Grant credit where it’s due and PR probably has a place in the ongoing development. Unfortunately for PR I think his actions over the last 18 months in regards to his positioning within and externally to PAR have attracted deserved criticism. I can’t imagine we would be in this position if Marco stayed as CEO. PR’s attempt at creating interest prior to the CR (regarding no need for CR) was an abject failure and created more credibility issues. His statement around MPS results might be seen as a ‘throwaway’ to indicate results were near but in the end it reflects poor judgement for someone you want at that level. The changes will come I guess but PR could be seen as damaged goods as CEO. It’s too easy to shoot him down for recent performance and the current SP. I try to focus on MPS results when they come, 2mg dose and hopefully that elusive deal. When these come together, there should be a change in sentiment although I believe we would benefit from the new Chair appointing a new CEO.